• Circadian Technologies Ltd., of Melbourne, Australia, said the FDA approved the investigational new drug application filed by its wholly owned subsidiary, Vegenics Pty Ltd., to initiate clinical trials of VGX-100, a human antibody that acts against the human VEGF-C protein. The Phase I study will evaluate VGX-100 in a variety of late-stage cancers.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter